$16.50 0.20 (+1.23%)
11/6/2009 4:00 PM

BioMarin Pharmaceutical, Inc. (BMRN)

CAPS Rating: 4 out of 5

The Company develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions.

Current Price $16.50 Mkt Cap $1.66B
Open $16.22 P/E Ratio 35.43
Prev. Close $16.30 Div. (Yield) N/A (N/A)
Daily Range $16.04 - $16.60 Volume 558,893
52-Wk Range $9.93 - $21.23 Avg. Daily Vol. 1,389,000

BMRN News and Commentary

Caps

How do you think BMRN will perform vs the S&P 500?

Add Stock to Watchlist

All Members

866 Outperform
43 Underperform
 

All-Star Members

209 Outperform
14 Underperform
 

Wall Street

15 Outperform
1 Underperform
 

Top BMRN Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

ResearchLover (74.95)
Submitted March 05, 2009

Looking for a bounce off todays 52-week low...sometime in the next 12 months seems reasonable.

nonothing2 (< 20)
Submitted August 18, 2008

THis company is in a good market because Pharmeceuticals will always be needed, but a PE ration of 659 is simply unsustainable. A PE of above 40 is high, but this companies stock is over 600 times more expensive than its earnings per share. That's… More

BMRN VS S&P 500 (SPY)

Fools bullish on BMRN are also bullish on:

Recent Community Commentary

Read the most recent pitches from members about BMRN.

Recs

0
Member Avatar topsecret09 (45.57) Submitted: 10/1/2009 11:36:45 PM : Outperform Start Price: $17.70 BMRN Score: -11.79


BioMarin has developed and commercialized three products in ten years, a remarkable accomplishment in the biopharmaceutical industry, and a testament to the company’s passion and dedication to patients with serious, unmet medical needs.
BioMarin has three approved products on the market today:
•Kuvan® (sapropterin dihydrochloride) Tablets for PKU
•Naglazyme® (galsulfase) for MPS VI
•Aldurazyme® (laronidase) for MPS I The year 2008 was a very important milestone in BioMarin’s history. We achieved our first profitable full year, with total revenues up 144 percent from 2007 to nearly $300 million, and increased sales across all of our three products. We continue to build an exciting pipeline, with a clinical portfolio featuring PEG-PAL for PKU and GALNS for MPS IVA, and a preclinical lineup that provides hope to many other patients with a variety of other rare diseases.
The year also brought with it the U.S. launch of Kuvan and we have been encouraged by the progress made thus far in a market with unique complexities. We continue to look for new ways to enhance our commercial efforts in this area and we remain very optimistic about the long-term potential of the product.
Other successes throughout the year included several regulatory achievements such as the approval of Naglazyme in Japan and South Korea, and the recent approval of Kuvan secured in the European Union by our partner Merck Serono.
In 2008, BioMarin achieved important milestones that will fuel future growth opportunities in the orphan drug industry. Today, as a fully integrated mid-cap biopharmaceutical company with three products on the market, strong revenues and cash reserves of nearly $560 million, we are confident and well positioned for the long-term. In 2009, we will continue to advance our pipeline and actively pursue valuable business development opportunities to bring increased value to patients, shareholders and employees. Logical buyout candidate In the BIOTECH field,should reward shareholders Into the future... TS

Recs

0
Member Avatar SierraBlue (< 20) Submitted: 9/16/2009 5:53:53 PM : Outperform Start Price: $17.63 BMRN Score: -6.85

Telechart Scan - Price Up 12.5% & Volume > 200K Last 20 Days

Recs

0
Member Avatar bestdamstockpkr (74.53) Submitted: 9/11/2009 7:26:46 AM : Outperform Start Price: $17.62 BMRN Score: -8.97

i usually don't by based soley on a recommendation without researching it my self, but I did this one. probably a mistake?

Leaderboard

Find the members with the highest scoring picks in BMRN.

Score Leader

farhangp

farhangp (66.87) Score: +137.68

The Score Leader is the member with the highest score across all their picks in BMRN.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score Commentary
TMFBreakerCharly 99.09 4/27/2006 5/27/2009 Outperform 3Y $12.13 +36.03% -11.61% +47.64 2 Comments
darthtater1 79.20 1/23/2009 Underperform 5Y $18.81 -12.28% +34.79% +47.07
BreakerBeth 79.10 5/17/2006 Outperform 5Y $12.26 +34.58% -10.74% +45.33 1 Comment
ecabiac 82.56 10/8/2008 Underperform NS $22.89 -27.92% +12.89% +40.81 1 Comment
theSith 44.38 2/13/2008 Underperform 1Y $40.15 -58.90% -18.12% +40.79
africansuperman < 20 3/4/2008 Underperform NS $37.43 -55.92% -15.57% +40.35
TrackOptionAddct 92.82 3/10/2008 Underperform 3W $35.71 -53.79% -13.99% +39.80
HalliSt 24.77 5/12/2008 Underperform 1Y $39.14 -57.84% -20.21% +37.63
duchey 90.82 1/14/2008 Underperform 1Y $39.45 -58.17% -20.91% +37.27
farmerellis 97.67 3/17/2008 Underperform NS $32.32 -48.95% -11.79% +37.16

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackCreditSuiss 91.16 10/30/2009 Outperform NS $17.56 -6.04% +1.84% -7.88
TrackJimCramer < 20 9/16/2009 Underperform 3W $17.48 -5.61% +0.62% +6.22
TrackMorganJos < 20 4/21/2009 Outperform NS $12.26 +34.58% +30.71% +3.88
TrackFTNEquityCa 25.15 3/12/2009 Outperform NS $10.24 +61.13% +49.65% +11.48
TrackLeerinkSwan 84.26 3/12/2009 Outperform NS $10.36 +59.27% +50.13% +9.14
TrackRothCapital 75.81 2/24/2009 Outperform NS $12.09 +43.34% +47.39% -4.05 10/19/2009 @ $17.33
TrackBreanMurray 89.84 1/9/2009 Outperform NS $19.20 -14.06% +19.60% -33.66
TrackBenchmark 88.54 1/7/2009 Outperform NS $18.11 -26.28% -12.60% -13.68 2/19/2009 @ $13.35
TrackCitigroup 21.22 11/21/2008 Outperform NS $14.42 +14.42% +42.52% -28.09
TrackZacks 69.52 10/29/2008 Outperform 3M $18.01 -34.43% -17.74% -16.68 2/20/2009 @ $11.81 1 Comment
TrackWMBlair 39.74 9/12/2008 Outperform NS $27.29 -39.54% -11.08% -28.45
TrackCollinsStew 68.32 8/21/2008 Outperform NS $25.84 -48.33% -36.37% -11.96 2/19/2009 @ $13.35
TrackSoleil 83.54 8/6/2008 Outperform NS $29.06 -43.22% -13.59% -29.63
TrackUBS 86.41 7/25/2008 Outperform NS $31.78 -48.08% -12.35% -35.73
TrackJefferies 75.83 11/6/2007 Outperform NS $28.25 -41.59% -25.60% -15.99
TrackWachovia 35.10 10/11/2007 Outperform NS $27.34 -51.17% -49.00% -2.17 2/19/2009 @ $13.35
TrackCitigroup 21.22 9/28/2007 Outperform NS $24.14 +38.82% -11.38% +50.19 6/12/2008 @ $33.51
TrackZacks 69.52 8/9/2007 Outperform 3M $21.48 -5.07% -32.04% +26.96 10/20/2008 @ $20.39 1 Comment
TrackFerrisBaker 72.41 7/26/2007 Outperform NS $18.37 -10.18% -24.55% +14.38
TrackAGEdwards 89.12 2/16/2007 Outperform NS $20.30 -18.72% -21.85% +3.13
TrackRodmanRen < 20 12/19/2006 Outperform NS $16.82 -1.90% -19.60% +17.70
TrackBroadpoint.AmTech 73.02 10/10/2006 Outperform NS $16.09 +2.55% -15.84% +18.39
TrackRWBaird 85.02 10/2/2006 Outperform NS $15.00 +10.00% -14.83% +24.83
TrackJimCramer < 20 5/25/2006 Outperform 3W $13.00 +34.46% -16.67% +51.13 9/17/2009 @ $17.48

Featured Broker Partners